When the blood vessels from the heart to the lungs tighten up, causing high blood pressure, doctors call it pulmonary arterial hypertension (PAH). It’s like a traffic jam in the lungs. PAH is just one type of pulmonary hypertension (PH), a condition when the blood vessels in the lungs are narrower than usual, making it harder for blood to flow through.
The underlying causes of PAH are complex, but studies have shown that a molecule called prostacyclin is related to the condition. This article explains what you need to know about prostacyclin and PAH.
Also called prostaglandin I-2, prostacyclin is a naturally occurring chemical in the body. Injury or inflammation triggers the innermost layer of endothelial cells (blood vessels) throughout the body to make and release prostacyclin.
Prostacyclin travels from the inside layer to other parts of blood vessels, activating nearby receptors. This works similarly to putting a key into a lock. Once prostacyclin links to these receptors, it causes the following actions:
People with PAH show lower amounts of prostacyclin in their bodies. Researchers believe that an imbalance between prostacyclin and other molecules may lead to PAH.
Proliferation of smooth muscle happens when extra cells grow in the walls of the blood vessels. This can lead to hypertension (high blood pressure). Prostacyclin helps counteract this process.
People with PAH show lower amounts of prostacyclin circulating in their bodies. This finding has led researchers to conclude that an imbalance between prostacyclin and other molecules may lead to PAH.
Lower amounts of prostacyclin in the body cause the blood vessels in the lungs to narrow, leading to vascular disease (disease of the blood vessels) and the symptoms of PAH. Many PAH medications approved by the U.S. Food and Drug Administration (FDA) affect the prostacyclin pathway to help lessen symptoms and slow down the disease.
Because people with PAH have lower amounts of prostacyclin circulating in their bodies, they don’t get the benefits of the chemical. Instead, they experience higher levels of inflammation, smooth muscle overgrowth of their blood vessels, blood clotting, and a narrowing of blood vessels.
Treatments for PAH include:
In cases of severe PH, a lung transplant may be necessary. All of these therapies work in different ways to improve blood flow and decrease pulmonary artery pressure.
Prostacyclin medications help to decrease inflammation, block smooth muscle overgrowth, limit blood clotting, and open blood vessels.
Doctors sometimes prescribe a newer type of treatment for PAH called prostacyclin analogs (prostanoids). These medications help to counter prostacyclin imbalances by acting as stand-ins for the body’s prostacyclins.
Prostacyclin medications help to decrease inflammation, block smooth muscle overgrowth, limit blood clotting, and open blood vessels. They act the same as natural prostacyclin in the body.
Doctors usually recommend prostacyclin analogs for people with PAH who are in a higher-risk group, have more advanced PAH or who are not responding well to other therapies. It can be used for monotherapy (a stand-alone medication) or in combination therapy (multiple medications).
Getting the dose right with prostacyclins can be difficult. Also, people on prostacyclins for PAH can develop a tolerance to the medication — along with unwanted side effects.
Like most pharmaceutical drugs, prostacyclin drugs are linked to the risk of side effects. They may include any of the following:
In addition, injectable forms of prostacyclin drugs — such as subcutaneous treprostinil — can cause pain at the injection site.
Talk to your doctor about any effects you experience after starting or switching PAH medications. They can help you understand what’s normal and what’s a cause for concern. They can also explain whether side effects will diminish over time or if there are ways to lessen their severity.
Importantly, tell your doctor if worsening side effects are making it difficult for you to stick with your treatment.
Based on results from clinical trials, the U.S. Food and Drug Adminisration (FDA) has approved two types of prostacyclin therapy for treating PAH: prostacyclin analogs and prostacyclin IP receptor agonists.
Unlike prostacyclin analogs, a prostacyclin receptor agonist doesn’t try to copy the shape of the body’s own prostacyclin. However, a prostacyclin receptor agonist still acts like the body’s own prostacyclin and has a similar effect on the body as natural prostacyclin.
The Pulmonary Hypertension Association offers several resources that can help people afford their medications.
Prostacyclin analogs include:
The one FDA-approved prostacyclin IP receptor agonist is selexipag, sold as Uptravi. It’s available in tablet form.
People need careful dose monitoring and adjustments by their doctor when taking any of these medications.
Other groups of medications for the treatment of PAH include endothelin receptor antagonists and phosphodiesterase-5 (PDE-5) inhibitors.
Examples of endothelin receptor antagonists include:
Examples of PDE-5 inhibitors include sildenafil (Revatio) and tadalafil (Adcirca).
Many treatments for PAH, including prostacyclin drugs, are expensive in the United States. The Pulmonary Hypertension Association recommends resources that can help people afford their medications. These resources include programs offered through drug manufacturers.
You can also ask your health care provider about resources to make medications more affordable.
On myPHteam, the online social network for people with pulmonary hypertension and their loved ones, more than 53,000 members come together to ask questions, give advice, and share their stories.
Are you living with pulmonary arterial hypertension? Have you taken prostacyclin analogs for your symptoms? Share your experience in the comments below, or start a conversation by posting on your Activities page.
Get updates directly to your inbox.
Is Lenus Pro Implantable Pump With Treprostinil Good For Me With PAH?? Doctors Are Really Persuading Me To Fix It. Tell Me Is It Really Good
Become a member to get even more:
A myPHteam Subscriber
This was extremely interesting and helpful. I may take this article to my pulmonologist at my next appointment!
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.